In a non-prespecified interim analysis of a phase 1 trial, autologous PRAME-directed TCR T cell therapy was safe and elicited durable responses in patients with recurrent and/or treatment-refractory PRAME+ advanced solid tumors, including melanoma and synovial sarcoma.
- Martin Wermke
- Dejka M. Araujo
- Cedrik M. Britten